NEU 0.15% $13.13 neuren pharmaceuticals limited

Media News, page-102

  1. 411 Posts.
    lightbulb Created with Sketch. 1280
    Yes, I think you're right. If you were developing an orphan drug you'd think your best investment would be to target a disease that has no approved treatment yet. Apparently there are some 7000 rare diseases I think I read - so sounds like there must be plenty of others to choose from!
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.